<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Baseline features of the study population</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th>Patients 
     <italic>(N = 144)</italic>
    </th>
    <th>Group A 
     <italic>(N = 101)</italic>
    </th>
    <th>Group B 
     <italic>(N = 43)</italic>
    </th>
    <th>
     <bold>
      <italic>p-value</italic>
     </bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>
     <bold>Sex, males.</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>71 (49.3%)</td>
    <td>42 (41.6%)</td>
    <td>29 (67.4%)</td>
    <td>
     <bold>0.006</bold>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Age, years, mean (SD)</bold>
    </td>
    <td>60 ± 13,5</td>
    <td>64.9 ± 11.7</td>
    <td>50.6 ± 12.1</td>
    <td>
     <bold>&lt; 0.001</bold>
    </td>
   </tr>
   <tr>
    <td colspan="5">
     <bold>Risk Factors</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
   </tr>
   <tr>
    <td>
     <italic>IDU</italic>
    </td>
    <td>37 (25.7%)</td>
    <td>17 (16.9%)</td>
    <td>20 (46.5%)</td>
    <td>
     <bold>&lt; 0.001</bold>
    </td>
   </tr>
   <tr>
    <td>
     <italic>Heterosexual</italic>
    </td>
    <td>10 (7.0%)</td>
    <td>8 (7.9%)</td>
    <td>2 (4.7%)</td>
    <td>0.720</td>
   </tr>
   <tr>
    <td>
     <italic>MSM</italic>
    </td>
    <td>1 (0.7%)</td>
    <td>0</td>
    <td>1 (2.3%)</td>
    <td>0.290</td>
   </tr>
   <tr>
    <td> Nosocomial</td>
    <td>38 (26.4%)</td>
    <td>31 (30.6%)</td>
    <td>7 (16.3%)</td>
    <td>0.150</td>
   </tr>
   <tr>
    <td>
     <italic>Unknown</italic>
    </td>
    <td>58 (40.2%)</td>
    <td>45 (44.6%)</td>
    <td>13 (30.2%)</td>
    <td>0.138</td>
   </tr>
   <tr>
    <td colspan="5">
     <bold>HCV Genotypes</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
   </tr>
   <tr>
    <td>
     <italic>1a</italic>
    </td>
    <td>32 (22.2%)</td>
    <td>17 (16.8%)</td>
    <td>15 (34.9%)</td>
    <td>
     <bold>0.020</bold>
    </td>
   </tr>
   <tr>
    <td>
     <italic>1b</italic>
    </td>
    <td>51 (35.4%)</td>
    <td>44 (43.6%)</td>
    <td>7 (16.3%)</td>
    <td>
     <bold>0.002</bold>
    </td>
   </tr>
   <tr>
    <td>
     <italic>2</italic>
    </td>
    <td>37 (25.7%)</td>
    <td>31 (30.7%)</td>
    <td>6 (13.9%)</td>
    <td>
     <bold>0.038</bold>
    </td>
   </tr>
   <tr>
    <td>
     <italic>3</italic>
    </td>
    <td>18 (12.5%)</td>
    <td>5 (4.9%)</td>
    <td>13 (30.2%)</td>
    <td>
     <bold>&lt; 0.001</bold>
    </td>
   </tr>
   <tr>
    <td>
     <italic>4</italic>
    </td>
    <td>6 (4.2%)</td>
    <td>4 (4%)</td>
    <td>2 (4.7%)</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td>
     <bold>Duration of HCV infection, years (range)</bold>
    </td>
    <td>18 (10–25.5)</td>
    <td>20 (11–26)</td>
    <td>17 (9–23)</td>
    <td>0.199</td>
   </tr>
   <tr>
    <td>
     <bold>Log 10 HCV-RNA, IU/mL, median (range)</bold>
    </td>
    <td>6.00 (5.48–6.52)</td>
    <td>5.9 (5.6–6.5)</td>
    <td>6.2 (5.6–6.6)</td>
    <td>0.095</td>
   </tr>
   <tr>
    <td>
     <bold>Liver stiffness, Kpa, mean (SD)</bold>
    </td>
    <td>10,8 ± 9,9</td>
    <td>11.5 ± 11.2</td>
    <td>9.1 ± 5.2</td>
    <td>0.518</td>
   </tr>
   <tr>
    <td>
     <bold>Previous failure,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>32 (22.2%)</td>
    <td>29 (28.7%)</td>
    <td>3 (7.0%)</td>
    <td>
     <bold>0.004</bold>
    </td>
   </tr>
   <tr>
    <td>
     <bold>INF-based tx</bold>
    </td>
    <td>31</td>
    <td>28</td>
    <td>3</td>
    <td/>
   </tr>
   <tr>
    <td>
     <bold>DAAs-based tx</bold>
    </td>
    <td>1</td>
    <td>1</td>
    <td>0</td>
    <td/>
   </tr>
   <tr>
    <td colspan="5">
     <bold>Fibrosis stage,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
   </tr>
   <tr>
    <td>
     <italic>F0-F2</italic>
    </td>
    <td>78 (54.1%)</td>
    <td>51 (50.5%)</td>
    <td>27 (62.8%)</td>
    <td>0.203</td>
   </tr>
   <tr>
    <td>
     <italic>F3</italic>
    </td>
    <td>24 (16.7%)</td>
    <td>19 (18.8%)</td>
    <td>5 (11.6%)</td>
    <td>0.338</td>
   </tr>
   <tr>
    <td>
     <italic>F4</italic>
    </td>
    <td>42 (29.2%)</td>
    <td>31 (30.7%)</td>
    <td>11 (25.6%)</td>
    <td>0.689</td>
   </tr>
   <tr>
    <td>
     <bold>FIB-4 score median (range)</bold>
    </td>
    <td>2.02 (1.40–3.35)</td>
    <td>2.2 (1.5–3.4)</td>
    <td>1.6 (1.2–2.9)</td>
    <td>
     <bold>0.009</bold>
    </td>
   </tr>
   <tr>
    <td>
     <bold>APRI score median (range)</bold>
    </td>
    <td>0.40 (0.60–1.22)</td>
    <td>0.6 (0.4–1.2)</td>
    <td>0.7 (0.4–1.2)</td>
    <td>0.315</td>
   </tr>
   <tr>
    <td>
     <bold>MELD score median (range)</bold>
    </td>
    <td>7 (6.5–8.5)</td>
    <td>7.0 (6.0–8.0)</td>
    <td>7.0 (6.0–7-0)</td>
    <td>0.923</td>
   </tr>
   <tr>
    <td colspan="5">
     <bold>Child-Pugh class</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
   </tr>
   <tr>
    <td> A</td>
    <td>142 (98.6%)</td>
    <td>100 (99.1%)</td>
    <td>42 (97.7%)</td>
    <td>0.510</td>
   </tr>
   <tr>
    <td> B</td>
    <td>2 (1.4%)</td>
    <td>1 (0.99%)</td>
    <td>1 (2.3%)</td>
    <td>0.510</td>
   </tr>
   <tr>
    <td>
     <bold>Cirrhosis,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>46 (31.9%)</td>
    <td>34 (33.66%)</td>
    <td>12 (27.9%)</td>
    <td>0.562</td>
   </tr>
   <tr>
    <td>
     <bold>Oesophageal varices or portal hypertension,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>15 (10.4%)</td>
    <td>11 (10.89%)</td>
    <td>4 (9.3%)</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td colspan="5">
     <bold>Type of HCV therapy</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
   </tr>
   <tr>
    <td> SOF + RBV</td>
    <td>7 (4.8%)</td>
    <td>6 (5.9%)</td>
    <td>1 (2.3%)</td>
    <td>0.670</td>
   </tr>
   <tr>
    <td> SOF + SMV ± RBV</td>
    <td>5 (3.5%)</td>
    <td>4 (3.9%)</td>
    <td>1 (2.3%)</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td> SOF + LDV ± RBV</td>
    <td>21 (14.6%)</td>
    <td>15 (14.9%)</td>
    <td>6 (13.9%)</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td> SOF + DCV ± RBV</td>
    <td>13 (9.0%)</td>
    <td>10 (10%)</td>
    <td>3 (7%)</td>
    <td>0.750</td>
   </tr>
   <tr>
    <td> OMB + PTV/r + DAS ± RBV</td>
    <td>15 (10.4%)</td>
    <td>15 (14.9%)</td>
    <td>0</td>
    <td>
     <bold>0.006</bold>
    </td>
   </tr>
   <tr>
    <td> OMB + PTV/r + RBV</td>
    <td>2 (1.4%)</td>
    <td>2 (1.9%)</td>
    <td>0</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td> SOF + VEL ± RBV</td>
    <td>37 (25.7%)</td>
    <td>15 (14.9%)</td>
    <td>22 (51.2%)</td>
    <td>
     <bold>&lt; 0.001</bold>
    </td>
   </tr>
   <tr>
    <td> GLE + PIB</td>
    <td>24 (16.7%)</td>
    <td>17 (16.8%)</td>
    <td>7 (16.3%)</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td> GRZ + EBR ± RBV</td>
    <td>20 (13.9%)</td>
    <td>17 (16.8%)</td>
    <td>3 (7%)</td>
    <td>0.186</td>
   </tr>
   <tr>
    <td colspan="5">
     <bold>Duration of therapy</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
   </tr>
   <tr>
    <td>
     <italic>8w</italic>
    </td>
    <td>20 (13.9%)</td>
    <td>15 (14.9%)</td>
    <td>5 (11.6%)</td>
    <td>0.794</td>
   </tr>
   <tr>
    <td>
     <italic>12w</italic>
    </td>
    <td>101 (70.1%)</td>
    <td>67 (66.3%)</td>
    <td>34 (79.1%)</td>
    <td>0.164</td>
   </tr>
   <tr>
    <td>
     <italic>16w</italic>
    </td>
    <td>6 (4.2%)</td>
    <td>4 (3.9%)</td>
    <td>2 (4.65%)</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td>
     <italic>24w</italic>
    </td>
    <td>17 (11.8%)</td>
    <td>15 (14.9%)</td>
    <td>2 (4.65%)</td>
    <td>0.097</td>
   </tr>
   <tr>
    <td>
     <bold>Addition of RBV</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>33 (22.9%)</td>
    <td>24 (23.74%)</td>
    <td>9 (20.9%)</td>
    <td>0.829</td>
   </tr>
   <tr>
    <td>
     <bold>ALT, UI/L, median (range)</bold>
    </td>
    <td>50 (30–80)</td>
    <td>47 (26.5–78.5)</td>
    <td>58 (43–93)</td>
    <td>
     <bold>0.029</bold>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Total bilirubin, mg/dL, median (range)</bold>
    </td>
    <td>0.62 (0.45–0.85)</td>
    <td>0.65 (0.47–0.82)</td>
    <td>0.60 (0.40–0.87)</td>
    <td>0.323</td>
   </tr>
   <tr>
    <td>
     <bold>Serum creatinine, mg/dL, median (range)</bold>
    </td>
    <td>0.78 (0.61–0.93)</td>
    <td>0.78 (0.60–0.95)</td>
    <td>0.78 (0.62–0.90)</td>
    <td>0.795</td>
   </tr>
   <tr>
    <td>
     <bold>Platelets (×10^9/L), median (range)</bold>
    </td>
    <td>183.5 (140.5–217.5)</td>
    <td>184 (145–219)</td>
    <td>182 (137–214)</td>
    <td>0.936</td>
   </tr>
   <tr>
    <td>
     <bold>Albumin, mg/dL, median (range)</bold>
    </td>
    <td>4.0 (3.7–4.2)</td>
    <td>4.0 (4.7–4.2)</td>
    <td>4.0 (3.8–4.1)</td>
    <td>0.976</td>
   </tr>
   <tr>
    <td>
     <bold>Body mass index, median (range)</bold>
    </td>
    <td>25.3 (23.3–28.7)</td>
    <td>25.5 (23.8–29.1)</td>
    <td>25.1 (22.4–27.4)</td>
    <td>0.936</td>
   </tr>
   <tr>
    <td>
     <bold>Patients with at least 1 other comorbidity, n (%)</bold>
    </td>
    <td>101 (70.10%)</td>
    <td>79 (78.2%)</td>
    <td>22 (51.2%)</td>
    <td>
     <bold>0.002</bold>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Diabetes,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>20 (13.9%)</td>
    <td>16 (15.8%)</td>
    <td>4 (9.3%)</td>
    <td>0.431</td>
   </tr>
   <tr>
    <td>
     <bold>Hypertension,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>61 (42.4%)</td>
    <td>53 (52.5%)</td>
    <td>8 (18.6%)</td>
    <td>
     <bold>&lt; 0.001</bold>
    </td>
   </tr>
   <tr>
    <td>
     <bold>HBsAg positive,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>2 (1.4%)</td>
    <td>0</td>
    <td>2 (4.7%)</td>
    <td>0.087</td>
   </tr>
   <tr>
    <td>
     <bold>HIV infected,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>19 (13.2%)</td>
    <td>9 (8.9%)</td>
    <td>10 (23.3%)</td>
    <td>
     <bold>0.030</bold>
    </td>
   </tr>
   <tr>
    <td>
     <italic>N aviremic pts on ART, n (%)</italic>
    </td>
    <td>19 (100%)</td>
    <td>9 (100%)</td>
    <td>10 (100%)</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td>
     <italic>CD4</italic>
     <sup>
      <italic>+</italic>
     </sup>
     <italic>(cells/μl) median (range)</italic>
    </td>
    <td>85 (42–171)</td>
    <td>98 (50–171)</td>
    <td>83.5 (42–186.5)</td>
    <td>0.903</td>
   </tr>
   <tr>
    <td>
     <italic>CDC-C Stage n (%)</italic>
    </td>
    <td>7 (4.8%)</td>
    <td>4 (3.9%)</td>
    <td>3 (7%)</td>
    <td>0.650</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>Legend</italic>: 
   <italic>IDU</italic> Injecting drug user, 
   <italic>MSM</italic> Man who have sex with man, 
   <italic>INF</italic> Interferon, 
   <italic>DAA</italic> Direct antiviral agent, 
   <italic>SOF</italic> Sofosbuvir, 
   <italic>RBV</italic> Ribavirin, 
   <italic>SMV</italic> Simeprevir, 
   <italic>LDV</italic> Ledipasvir, 
   <italic>DCV</italic> Daclatasvir, 
   <italic>OMB</italic> Ombitasvir, 
   <italic>PTV/r</italic> Paripatrevir/ritonavir, 
   <italic>DSV</italic> Dasabuvir, 
   <italic>VEL</italic> Velpatasvir, 
   <italic>GLE</italic> Glecaprevir, 
   <italic>PIB</italic> Pibrentasvir, 
   <italic>GRZ</italic> Grazoprevir, 
   <italic>EBR</italic> Elbasvir, 
   <italic>ALT</italic> Alanine aminotransferase, 
   <italic>ART</italic> Antiretroviral therapy
  </p>
 </table-wrap-foot>
</table-wrap>
